Chang Lee, MD
Internal Medicine · Englewood Cliffs, NJNPI 1235152554
Payments from drug & device makers
Across 596 payments — averaging $13.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Novo Nordisk$1K
- AstraZeneca$605
- Lilly USA, LLC$394
- GSK$354
- Boehringer Ingelheim$336
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,98899%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 174 | $2,317 |
| Novo Nordisk | 107 | $1,406 |
| AstraZeneca(2 entities) | 42 | $605 |
| Lilly USA, LLC | 28 | $394 |
| GSK | 26 | $354 |
| Boehringer Ingelheim | 23 | $336 |
| AbbVie(2 entities) | 32 | $327 |
| Gilead | 20 | $291 |
| Astellas Pharma US Inc | 12 | $261 |
| Sanofi-aventis U.S. LLC | 18 | $249 |
| Amarin Pharma, Inc. | 22 | $204 |
| Pfizer | 12 | $176 |
| Exact Sciences | 3 | $147 |
| Exelixis Inc. | 16 | $137 |
| Kowa Pharmaceuticals America, Inc. | 9 | $120 |
| Johnson & Johnson | 6 | $83 |
| Esperion Therapeutics, Inc. | 5 | $71 |
| Insmed, Inc. | 4 | $64 |
| Radius Health, Inc. | 4 | $52 |
| Mannkind Corporation | 4 | $48 |
| Bayer | 3 | $45 |
| Dexcom, Inc. | 2 | $44 |
| Merck | 3 | $39 |
| Abbott | 2 | $34 |
| Lundbeck LLC | 2 | $31 |
| Corcept Therapeutics | 2 | $29 |
| Novartis | 2 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Regeneron Healthcare Solutions, Inc. | 2 | $26 |
| Eisai Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Vivus LLC | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cologuard Collection Kit$125
- Prolia$122
How this compares
$8,073 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 184 | $262,958 |
| ProliaDenosumab | 131 | $218,265 |
| JanumetSitagliptin Phos/Metformin Hcl | 103 | $105,064 |
| JardianceEmpagliflozin | 116 | $103,304 |
| FarxigaDapagliflozin Propanediol | 86 | $84,225 |
| JanuviaSitagliptin Phosphate | 78 | $83,577 |
| SynjardyEmpagliflozin/Metformin Hcl | 60 | $74,573 |
| TradjentaLinagliptin | 82 | $71,481 |
| Repatha SureclickEvolocumab | 63 | $69,261 |
| XareltoRivaroxaban | 48 | $54,990 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 48 | $51,159 |
| JentaduetoLinagliptin/Metformin Hcl | 82 | $49,229 |
| CreonLipase/Protease/Amylase | 44 | $44,206 |
| EliquisApixaban | 42 | $44,065 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 42 | $38,325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy, Tradjenta, Synjardy Xr, Jentadueto | $336 | $349,747388 claims |
| Novo NordiskOzempic | $1,406 | $262,958184 claims |
| MerckJanumet, Januvia, Janumet Xr | $39 | $226,966223 claims |
| AmgenProlia | $2,317 | $218,265131 claims |
| AstraZenecaFarxiga | $605 | $84,22586 claims |
| GSKBreo Ellipta, Anoro Ellipta, Trelegy Ellipta, Shingrix | $354 | $67,604118 claims |
| AbbVieCreon, Linzess | $327 | $65,10976 claims |
| Johnson & JohnsonXarelto | $83 | $54,99048 claims |
| PfizerEliquis | $176 | $44,06542 claims |
| Lilly USA, LLCTrulicity | $394 | $36,86328 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $14 | $19,99458 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $249 | $14,32216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Englewood Cliffs
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.